drugset / Trial / NCT00821587
Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the effect of cyclosporine, an anti-rejection drug, on the clearance of the hepatitis C virus in liver transplant subjects being treated with peg-interferon and ribavirin.
Timeline
- Start
- 2004-06
- Primary completion
- 2008-05
- Completion
- 2008-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclosporine | Peptide | 2 mg/kg | Oral |
| Comparator | Cyclosporine | Peptide | 4 mg/kg | Oral |
| Comparator | Tacrolimus | Small molecule | 0.08 mg/kg | Oral |
| Comparator | Tacrolimus | Small molecule | 0.12 mg/kg | Oral |